The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,002.00
Bid: 2,006.00
Ask: 2,008.00
Change: -10.00 (-0.50%)
Spread: 2.00 (0.10%)
Open: 2,014.00
High: 2,024.00
Low: 1,994.00
Prev. Close: 2,012.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

31 May 2023 15:20

RNS Number : 2161B
Hikma Pharmaceuticals Plc
31 May 2023
 

 

Hikma Pharmaceuticals PLC - LTIP and EIP Awards

 

LONDON, 31 May 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP"); the 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 30 May 2023 based on a price of £18.43 per Ordinary Share (being the average mid-market Ordinary Share price for the for the 5-working day period prior to 30 May 2023, in accordance with the LTIP rules) (the "LTIP Awards"). The vesting of the LTIP Awards is subject to the continued employment of the PDMRs, malus and clawback provisions and the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP Awards are then subject to an additional two-year holding period.

Awards under the EIP were made on 30 May 2023 based on a price of £15.15 per Ordinary Share (being the average mid-market Ordinary Share price for the 30-day period prior to 31 December 2022, in accordance with the EIP rules) (the "EIP Awards"). All EIP Awards are subject to malus and clawback provisions. EIP Element B Awards will normally vest on the second anniversary of the date of grant, subject to continued employment, and are then subject to an additional three-year holding period. EIP Element C Awards will normally vest on the third anniversary of the date of grant, subject to continued employment, and are then subject to an additional two-year holding period.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 132,783 Shares

Nil

EIP Award, Element B: 31,679 Shares

Nil

EIP Award, Element C: 19,761 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 184,223

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 105,233 Shares

Nil

EIP Award, Element B: 36,171 Shares

Nil

EIP Award, Element C: 20,650 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 162,054

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 76,130 Shares

Nil

EIP Award, Element B: 28,647 Shares

Nil

EIP Award, Element C: 20,982 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,759

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 74,699 Shares

Nil

EIP Award, Element B: 28,833 Shares

Nil

EIP Award, Element C: 22,209 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,741

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 75,339 Shares

Nil

EIP Award, Element B: 36,371 Shares

Nil

EIP Award, Element C: 30,749 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 142,459

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 50,301 Shares

Nil

EIP Award, Element B: 18,836 Shares

Nil

EIP Award, Element C: 13,796 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 82,933

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 38,409 Shares

Nil

EIP Award, Element B: 15,925 Shares

Nil

EIP Award, Element C: 11,664 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 65,998

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 54,422 Shares

Nil

EIP Award, Element B: 12,233 Shares

Nil

EIP Award, Element C: 8,302 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 74,957

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Hussein Arkhagha

 1

 Details of the person discharging managerial responsibilities / person closely associated

 a)

 Name

 Hussein Arkhagha

 2

 Reason for the notification

 a)

 Position/status

 PDMR

 b)

Initial notification /Amendment

 Initial notification

 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)

 Name

 Hikma Pharmaceuticals PLC

 b)

 LEI

 549300BNS685UXH4JI75

 4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 41,408 Shares

Nil

EIP Award, Element B: 15,983 Shares

Nil

EIP Award, Element C: 12,406 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 69,797

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

 

Helen Middlemist

Deputy Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDUCBXDGXB
Date   Source Headline
9th Mar 20225:53 pmRNSTransaction in Own Shares
8th Mar 20225:21 pmRNSTransaction in Own Shares
8th Mar 202210:21 amRNSHolding(s) in Company
7th Mar 20225:12 pmRNSTransaction in Own Shares
7th Mar 20221:36 pmRNSDirector/PDMR Shareholding
4th Mar 20226:20 pmRNSTransaction in Own Shares
3rd Mar 20225:44 pmRNSTransaction in Own Shares
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.